Program
Azacitidine
Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.
Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.
Drug pageAzacitidine: every studyMany companies study it; this page follows only the 27 they lead. All 441 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 161 open or running | phase 4since Sep 13, 2010 | Oct 31, 2003 | none ahead |
| Takedaits history only | 30 open or running | phase 3since Aug 30, 2017 | May 28, 2009 | none ahead |
| Hikma Pharmaceuticalsits history only | 21 open or running | phase 1since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| Bioniche Pharma USAits history only | 10 open or running | phase 1since Jun 25, 2010 | Jun 25, 2010 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Feb 7, 2020 | Feb 7, 2020 | none ahead |
| Merckits history only | 10 open or running | phase 2since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| Nanexa ABits history only | 10 open or running | phase 1since May 11, 2021 | May 11, 2021 | none ahead |
| Nob Hill Therapeuticsits history only | 11 open or running | phase 2since Sep 10, 2026 | Sep 10, 2026 | Jul 13, 2029phase 2 · NCT07864584 |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Oct 4, 2006 | Oct 4, 2006 | none ahead |
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical, Hoffmann-La Roche, Roche-Genentech, Takeda Development Center Americas and argenx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Oct 31, 2003.
- May 14, 2012Phase 2 study in Myelodysplastic SyndromesBristol-Myers Squibb · NCT01599325 · 72 enrolled · China
- Nov 24, 2014Merck’s first study: phase 2 study in Leukemia, Myeloid, AcuteNew to MerckMerck · NCT02303782
- Apr 14, 2015Phase 2 study in Myelodysplastic SyndromesBristol-Myers Squibb · NCT02447666 · 28 enrolled · Austria, Belgium, Czechia and more
- May 19, 2015Phase 2 study in Leukemia, Myeloid, AcuteBristol-Myers Squibb · NCT02450877 · 7 enrolled · Denmark, Germany, Netherlands
- Feb 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteBristol-Myers Squibb · NCT02677922 · 130 enrolled · United States, Australia, Belgium and more
- May 20, 2016Phase 1 study in Leukemia, Myeloid, AcuteTakeda · NCT02782468 · 23 enrolled · Japan, Korea, Republic of, Taiwan
- Aug 30, 2017Phase 3 study in Myelodysplastic SyndromesTakeda · NCT03268954 · 454 enrolled · United States, Australia, Belgium and more
- Oct 9, 2018Phase 3 study in Lymphoma, T-CellBristol-Myers Squibb · NCT03703375 · 93 enrolled · Japan
- Feb 7, 2020Johnson & Johnson’s first study: phase 2 study in Myelodysplastic SyndromesNew to Johnson & JohnsonJohnson & Johnson · NCT04264806 · Australia, Brazil, France and more
- Feb 2, 2021Phase 1 study in Leukemia, MyeloidBristol-Myers Squibb · NCT04748848 · 1 enrolled · United States, Belgium, France and more
- May 11, 2021Nanexa AB’s first study: phase 1 study in Myelodysplastic SyndromesNew to Nanexa ABNanexa AB · NCT05048498 · 2 enrolled · Sweden
- Mar 11, 2024Hikma Pharmaceuticals’ first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT06326697 · 32 enrolled · Saudi Arabia
- Aug 22, 2024No phase study in Leukemia, Myeloid, AcuteHikma Pharmaceuticals · NCT06572982 · 20 enrolled · United Arab Emirates
- Sep 10, 2026Nob Hill Therapeutics’ first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Nob Hill TherapeuticsNob Hill Therapeutics · NCT07864584 · 100 planned · United States
Ahead
- Jul 13, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNob Hill Therapeutics · NCT07864584
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07864584Carcinoma, Non-Small-Cell Lung · United States | 2 | Not yet recruiting | Nob Hill Therapeutics | Jul 13, 2029 | 100 |
| NCT06572982Leukemia, Myeloid, Acute · United Arab Emirates | – | Active, not recruiting | Hikma Pharmaceuticals | May 2026 | 20 |
| NCT06326697Leukemia, Myeloid, Acute · Saudi Arabia | 1 | Completed | Hikma Pharmaceuticals | Aug 17, 2025 | 32 |
| NCT05048498Myelodysplastic Syndromes · Sweden | 1 | Completed | Nanexa AB | Feb 10, 2022 | 2 |
| NCT04748848Leukemia, Myeloid · United States, Belgium, France and more | 1 | Terminated | Bristol-Myers Squibb | Mar 9, 2022 | 1 |
| NCT04264806Myelodysplastic Syndromes · Australia, Brazil, France and more | 2 | Withdrawn | Johnson & Johnson | Apr 19, 2022 | 0 |
| NCT03703375Lymphoma, T-Cell · Japan | 3 | Completed | Bristol-Myers Squibb | Feb 10, 2021 | 93 |
| NCT03268954Myelodysplastic Syndromes · United States, Australia, Belgium and more | 3 | Completed | Takeda | May 28, 2021 | 454 |
| NCT02782468Leukemia, Myeloid, Acute · Japan, Korea, Republic of, Taiwan | 1 | Completed | Takeda | Jan 25, 2022 | 23 |
| NCT02677922Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Aug 2, 2018 | 130 |
| NCT02450877Leukemia, Myeloid, Acute · Denmark, Germany, Netherlands | 2 | Completed | Bristol-Myers Squibb | Oct 10, 2018 | 7 |
| NCT02447666Myelodysplastic Syndromes · Austria, Belgium, Czechia and more | 2 | Completed | Bristol-Myers Squibb | Feb 28, 2018 | 28 |
| NCT02303782Leukemia, Myeloid, Acute | 2 | Withdrawn | Merck | Mar 2016 | 0 |
| NCT01599325Myelodysplastic Syndromes · China | 2 | Completed | Bristol-Myers Squibb | Jan 29, 2015 | 72 |
| NCT01358734Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | Bristol-Myers Squibb | May 19, 2015 | 88 |
| NCT01201811Myelodysplastic Syndromes · Taiwan | 4 | Completed | Bristol-Myers Squibb | May 1, 2013 | 44 |
| NCT01186939Myelodysplastic Syndromes · Australia, Bulgaria, France and more | 3 | Completed | Bristol-Myers Squibb | Sep 1, 2009 | 40 |
| NCT01152346Myelodysplastic Syndromes · United States, France | 1 | Completed | Bioniche Pharma USA | Dec 2012 | 19 |
| NCT01074047Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jan 22, 2014 | 488 |
| NCT00911066Leukemia, Myeloid, Acute · United States | 1 | Completed | Takeda | Aug 2013 | 72 |
| NCT00761722Leukemia, Myeloid, Acute · United States | 1 | Completed | Bristol-Myers Squibb | Apr 6, 2016 | 31 |
| NCT00666497Leukemia, Myeloid, Acute · United States, Canada, United Kingdom | 2 | Terminated | Bristol-Myers Squibb | Apr 2009 | 6 |
| NCT00652626Multiple Myeloma · United States | 1 | Completed | Bristol-Myers Squibb | Jul 1, 2012 | 31 |
| NCT00528983Myelodysplastic Syndromes · United States | 1 | Completed | Bristol-Myers Squibb | Jul 31, 2013 | 133 |
| NCT00384839Prostatic Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Nov 2009 | 36 |
| NCT00102687Myelodysplastic Syndromes · United States | 2 | Completed | Bristol-Myers Squibb | Aug 1, 2008 | 151 |
| NCT00071799Myelodysplastic Syndromes · United States, Australia, Bulgaria and more | 3 | Completed | Bristol-Myers Squibb | Jul 1, 2007 | 358 |
How it is read
Names in the registry
- “Azacitidine”, 36 entries
- “azacitidine”, 8 entries
- “Azacitidine (AZA)”, 2 entries
- “Eganelisib in combination with azacitidine”, 1 entry
- “NHT102”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 30 studies
- Myelodysplastic Syndromes, 18 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hematologic Neoplasms, 1 study
- Lymphoma, T-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.